ICD-10 Code D09.3
Carcinoma in situ of thyroid and other endocrine glands
D09.3 is a medical classification code used for carcinoma in situ of other and unspecified thyroid and other endocrine glands. Carcinoma in situ represents an early, non-invasive stage of cancer where severely abnormal cells are confined to the tissue layer of origin without penetrating the basement membrane or invading adjacent anatomical structures. In clinical practice, this diagnosis indicates pre-invasive neoplastic changes within various hormone-producing tissues, requiring surgical resection or vigilant surveillance to prevent progression to invasive malignancy. This code applies to conditions affecting the thyroid gland, adrenal glands, parathyroid glands, pituitary gland, pineal gland, craniopharyngeal duct, and extra-adrenal paraganglia such as the carotid or aortic bodies. Related conditions and diagnostic concepts associated with this code include endocrine intraepithelial neoplasia, non-invasive neuroendocrine tumors in situ, high-grade thyroid dysplasia, pre-invasive adrenal cortical lesions, and localized parathyroid neoplasms.
D09.3 is a valid billable ICD-10 diagnosis code for Carcinoma in situ of thyroid and other endocrine glands. It is found in the 2027 version of the ICD-10 CM Index and can be used in all HIPAA-covered transactions from Oct 01, 2026 - Sep 30, 2027.
Check for any exclusions, inclusions or special notations associated with D09.3
See also, ICD-10 Table of Neoplasms.
- MDC 17 Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms
Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major Procedure- DRG 826 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITH MCC
- DRG 827 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITH CC
- DRG 828 - MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURE WITHOUT CC/MCC
- MDC 17 Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms
Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedure - MDC 17 Myeloproliferative Diseases & Disorders, Poorly Differentiated Neoplasms
Other Myeloproliferative Disorders or Poorly Differentiated Neoplasm Diagnoses- DRG 843 - OTHER MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASTIC DIAGNOSES WITH MCC
- DRG 844 - OTHER MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASTIC DIAGNOSES WITH CC
- DRG 845 - OTHER MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASTIC DIAGNOSES WITHOUT CC/MCC
ICD-10 code D09.3 is based on the following Tabular structure:
Chapter 2: Neoplasms- Section D00-D09: In situ neoplasms
- Category D09: Carcinoma in situ of other and unspecified sites
Should you use D09.3 or D093 (with or without decimal point) when submitting claims?
DO NOT include the decimal point when electronically filing claims as it may be rejected. Some clearinghouses may remove it for you
but to avoid having a rejected claim due to an invalid ICD-10 code, do not include the decimal point when submitting claims electronically.
This note further define, or give examples of, the content of the code or category.
List of terms is included under some codes. These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of “other specified” codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10 CM has a coding convention that requires the underlying condition be sequenced first, if applicable, followed by the manifestation. Wherever such a combination exists, there is a “use additional code” note at the etiology code, and a “code first” note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
A type 1 Excludes note is a pure excludes. It means 'NOT CODED HERE!' An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
A type 2 Excludes note represents 'Not included here'. An Excludes2 note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When an Excludes2 note appears under a code it is acceptable to use both the code and the excluded code together.
A “code also” note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction. The sequencing depends on the circumstances of the encounter.
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10 CM has a coding convention that requires the underlying condition be sequenced first, if applicable, followed by the manifestation. Wherever such a combination exists, there is a “use additional code” note at the etiology code, and a “code first” note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.